Skip to main
EVAX

EVAX Stock Forecast & Price Target

EVAX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evaxion is a clinical-stage TechBio company with a promising platform, AI-Immunology, that utilizes artificial intelligence to develop novel vaccines for cancer and infectious diseases. The company's clinical pipeline is strong, with its lead personalized neoantigen vaccine, EVX-01, showing impressive efficacy and 86% immunogenicity in phase 2 trials. With a CEO known for engineering credible transactions and a strong balance sheet, Evaxion is well-positioned to capitalize on any potential business development opportunities in 2026, making it a promising investment option for the future.

Bears say

Evaxion is facing significant financial challenges due to its high operational burn rate of $14.0M coupled with minimal revenue generation of $7.5M in FY25, resulting in a net loss of $0.20 per diluted share. Furthermore, the preclinical stage of Evaxion's pipeline and absence of any approved products poses a high risk for investors, making the stock unattractive. Despite raising $30M in gross proceeds in 2025, Evaxion's current financial status and lack of near-term catalysts does not provide a positive outlook for the company's stock in the near future.

EVAX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evaxion Biotech A/S (EVAX) Forecast

Analysts have given EVAX a Strong Buy based on their latest research and market trends.

According to 4 analysts, EVAX has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evaxion Biotech A/S (EVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.